| Detailed information |
|---|
| CancerLivER ID | 2428 |
| Biomarker | IGFBP7 |
| Biomarker Name/Symbol (given in Publication) | IGFBP7 |
| Biomolecule | Protein and RNAs |
| Subject | Human |
| Degree of Validity | IGFBP7 is a potentially useful marker for the prediction of clinical response to IFN-α/5-FU therapy. |
| Experimental Condition | IGFBP7-positive HCC patients v/s IGFBP7-negative HCC patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in IFN-resistant cells (with fold change 2.963) |
| Level of significance | p < 0.05 |
| Source | Cell line and Tissue |
| PMID | 20407444 |
| Type of Biomarker | Predictive |
| Pathway | Insulin-like growth factor binding |
| Cohort | Human HCC cell lines, PLC/PRF/5 and HLE ; 10 clones of PLC/PRF/5 cells resistant to IFN-α were established. The clones were confirmed as being resistant to IFN-α stably over 20 passages. Among the 10 clones, three clones (PLC-Rs; PLC-R1, PLC-R2, and PLC-R3) were used in the experiments of this stu |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | IGFBP7-positive HCC patients v/s IGFBP7-negative HCC patients |
| Year of Publication | 2010 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |